RxDoctor Payments Data

Shelly Larson-Peters, MD

Neurology · Blaine, MNNPI 1336333509

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $115,076 of the $142,967 with a category attached, or 80.5%. 5 manufacturers reported payments, led by Biogen at 46.2% of the total. Among neurology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$142,967in general payments, 2019–2025

Across 156 payments — averaging $916.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$66K
  • TG Therapeutics, Inc.$32K
  • Sanofi$31K
  • Teva Pharmaceuticals USA, Inc.$13K
  • Genentech USA, Inc.$374

What the payments were for

  • Consulting fees$18,75413%
  • Speaking & faculty fees$115,07680%
  • Travel & lodging$6,4535%
  • Food & beverage$2,6852%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen65$66,039
TG Therapeutics, Inc.27$32,053
Sanofi47$31,479
Teva Pharmaceuticals USA, Inc.13$13,022
Genentech USA, Inc.4$374

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$142,967 in reported general payments places this provider in the 95th percentile of 434 neurology providers in Minnesota.

See all neurology providers in Minnesota

Medicare billing

Part B allowed, 2024
$401,064
Medicare patients
462
Services billed
21,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate110$659,938
Kesimpta PenOfatumumab26$242,292
AubagioTeriflunomide24$223,479
Teriflunomide28$153,940
Avonex Pen (4 Pack)Interferon Beta-1a14$151,492
GlatopaGlatiramer Acetate61$142,106
Glatiramer Acetate59$124,926
Nurtec OdtRimegepant Sulfate37$49,604
UbrelvyUbrogepant24$22,203
Aimovig AutoinjectorErenumab-Aooe22$20,393
Modafinil64$17,014
Emgality PenGalcanezumab-Gnlm16$12,235
FingolimodFingolimod Hcl12$7,542
Gabapentin238$5,951
Levetiracetam106$3,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$13,022$659,938110 claims
SanofiAubagio$31,479$223,47924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 neurology providers in Minnesota.

Other neurology in Blaine

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →